Thomas Bauknecht - Concepedia

Author

Thomas Bauknecht

Also Known As

Juan-Jose Hernando, T BAUKNECHT, T Bauknecht, T. BAUKNECHT, T. Bauknecht, THOMAS BAUKNECHT, Thomas Bauknecht, W. Sauerbrei

105

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

University of Freiburg Universitäts Frauenklinik Eli Lilly (Germany)Eli Lilly (United States)Charité - Universitätsmedizin Berlin

About

Thomas Bauknecht is an author at University of Freiburg specializing in medicine, obstetrics, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	1.7K
2	Public Health	3	3	366
3	Health Sciences	2	2	35
4	Allergy	1	1	106
5	Biomolecular Engineering	1	1	16

Thomas Bauknecht

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial Willemien J. van Driel, Maaike E. Ressing, Gemma G. Kenter, European Journal of Cancer VaccinationCancer-associated VirusVaccine DevelopmentCervical HealthCervical Cancer	1999	230
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential Ivo Meinhold‐Heerlein, Dirk Bauerschlag, Felix Hilpert, Oncogene Prognostic DistinctionTumoral PathologyMedicinePathologyGynecology	2004	205
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Andreas M. Kaufmann, Peter L. Stern, Elaine M. Rankin, PubMed	2002	204
Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma Maaike E. Ressing, Willemien J. van Driel, Remco M.P. Brandt, Journal of Immunotherapy	2000	172
Differential chromatid staining by in vivo treatment as a mutagenicity test system Walther Vogel, Thomas Bauknecht Nature PathologyToxicology TestingToxicologyMutagenicity Test SystemVivo Treatment	1976	150
The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Manuela Kohler, Ingo Janz, Hanns-Olof Wintzer, PubMed Egf-like FactorsC-myc ExpressionPathologyGynecologyTumor Biology	1989	113
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Uwe Wagner, Siegmund Köhler, Silke Reinartz, PubMed Serious Allergic ReactionsImmunologyImmunoeditingRecurrent Ovarian CancerImmune Cell Therapy	2001	106
PROutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer Gesine Benze, Friedemann Nauck, Bernd Alt‐Epping, Annals of Palliative Medicine	2017	106
Phase II study of gemcitabine in ovarian cancer Gϋnter von Minckwitz, Thomas Bauknecht, Carla Visseren‐Grul, Annals of Oncology MedicineGynecologyCancer TreatmentOncologyOvarian Cancer	1999	94
The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer Thomas Bauknecht, Manuela Kohler, Ingo Janz, Journal of Cancer Research and Clinical Oncology Egf-like FactorsGynecologyEpithelial-mesenchymal InteractionsBreast CancerDermatology	1989	82

Page 1